It is all about % not the actual amount. Buying 1000 shares at $1.65 puts $1,650 at risk and a 3.6% increase in one day yields $59.40
Purchasing 1000 shares of Apple at $94.00 per share puts $94,000 at risk and a 3.6% increase in one day yields $3,384.
Probably, but the plan then was most likely based on the idea that the revenue stream from Belviq would be larger. It's also very difficult for R&D scientists to make decisions to lay off fellow scientists and research types. Munshi was able to come in and look at financials and do what had to be done in order to survive.
Munshi didn't join Arena and take a 3.8 million share option package at $1.55 a share which vests over the next few years and plan to fail. Cutting R&D staff and focusing on the multiple compounds already in trials was the right call.
I would disagree. For a small cap pharma, there are plenty of compounds already being evaluated and in agreements with JV pharmas. It's time to reduce spending on more research & patent filing and move forward with compounds already in clinical trials, etc.
Focus on finances & moving compounds already in clinical trials along. Probably don't need to have staff continue to do R&D lab work & file patents. Old management were Phds who could only focus on science R&D and not finances. There is an old saying in the world of R&D; Sometimes scientists & engineers need adult supervision"
Since this board has nothing to do with thought out views, I thought I'd post something just as silly. :-)
$10 in 2017 is likely though.
Sentiment: Strong Buy
Why would he buy shares on the open market? He has 3.8 million shares in options which he can exercise over the next few years at the closing price on May 11 which was $1.55 He will make his money by moving the stock price higher and exercising his options.
Isn't it funny that there are thumbs down when just a basic fact is reported?
After 2 pm the volume picked up quite a bit. 64K shares traded at 3:45 pm, followed by more volume and a little uptick in share price. I'd say someone is accumulating shares. Now is the time to being buying ARNA shares. No disagreement with anyone that past 1.5 years has not been pleasant, but there is a future. Belviq is still selling, multiple compounds coming along well in Phase II trials, new CEO who is a business money guy and not a scientist, multiple business partnerships in place.
Your statement "a cursory look" says it all. No doubt a quick look at the chart for the past 1.5 years is not good. At this point one has to look at ARNA as any other small pharma with a pipeline of compounds in development. That is where the value will come from.
A good history of my posts. One thing missing is when I have sold. I never post those actions. Don't own every share I have ever purchased. My current ave share price is very low.
As ARNA, VVUS, and OREX put their Rx obesity drugs on the market, everyone was hoping for the hay-days of the early 90's when prescription rates for Redux (Fen-Phen) were 85,000 per week. Didn't happen and all three have had the share price drop. ARNA wisely partnered with Eisai rather than spending $350 million to market Belviq on their own. Income and fees have gone to improve Belviq and develop other compounds. ARNA has multiple other compounds in Phase I and II trials, plus partnerships on others. At $1.88 I am willing to buy a few thousand more shares. NOW CONTINUE WITH THE DAILY FOOD FIGHT
Sentiment: Strong Buy
That is the pipeline that has been shut down and impacted CVRR. No other Magellan pipelines have been shut down. It takes a bit of searching to verify that this is true. Early reports claiming it was a pipeline between Coffeyville and Oklahoma City were just wrong.
do you think the operators of the Magellan pipeline just woke up one morning last week and said "hey, let shut down the 30,00 bbl per day product pipeline we operate that connects Coffeyville CRV to Kansas City? I don't know what is exactly going on, but I bet alternate modes of product transport are in play.